These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32531309)

  • 1. An identification and functional evaluation of a novel CYP2C9 variant CYP2C9*62.
    Chen H; Dai DP; Zhou S; Liu J; Wang SH; Wu HL; Zhou Q; Geng PW; Chong J; Lü Y; Cai JP; Yang JF
    Chem Biol Interact; 2020 Aug; 327():109168. PubMed ID: 32531309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a novel CYP2C9 mutation (1009C>A) detected in a warfarin-sensitive patient.
    Luo SB; Li CB; Dai DP; Wang SH; Wang ZH; Geng PW; Cai J; Jiang ZL; Pu CW; Shang K; Yuan XM; Cao YP; Hu GX; Cai JP
    J Pharmacol Sci; 2014; 125(2):150-6. PubMed ID: 25075423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional characterization of the defective CYP2C9 variant CYP2C9*18.
    Liu J; Chen H; Wang SH; Zhou Q; Geng PW; Zhou YF; Wu HL; Shi HF; Wang F; Yang JF; Cai JP; Dai DP
    Pharmacol Res Perspect; 2021 Feb; 9(1):e00718. PubMed ID: 33508175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and Functional Assessment of a New CYP2C9 Allelic Variant CYP2C9*59.
    Dai DP; Wang SH; Li CB; Geng PW; Cai J; Wang H; Hu GX; Cai JP
    Drug Metab Dispos; 2015 Aug; 43(8):1246-9. PubMed ID: 25994031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of a novel CYP2C9 allelic variant in a warfarin-sensitive patient.
    Dai DP; Li CB; Wang SH; Cai J; Geng PW; Zhou YF; Hu GX; Cai JP
    Pharmacogenomics; 2015; 16(13):1475-86. PubMed ID: 26255664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin: Results of a 5 years audit.
    Biswas M; Bendkhale SR; Deshpande SP; Thaker SJ; Kulkarni DV; Bhatia SJ; Rajadhyaksha AG; Gogtay NJ; Thatte UM
    Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S13-S19. PubMed ID: 30595245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.
    Farzamikia N; Sakhinia E; Afrasiabirad A
    Lab Med; 2017 Dec; 49(1):25-34. PubMed ID: 29182754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population.
    Dilge Taşkın B; Kula S; Ergün MA; Altun D; Olguntürk R; Tunaoğlu FS; Oğuz AD; Gürsel T
    Anatol J Cardiol; 2016 Oct; 16(10):791-796. PubMed ID: 27182616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene-gene interactions on warfarin therapy.
    Khalighi K; Cheng G; Mirabbasi S; Khalighi B; Wu Y; Fan W
    J Thromb Thrombolysis; 2017 Jan; 43(1):124-129. PubMed ID: 27743182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Genetic Polymorphisms in the VKORC1 and CYP2C9 Genes with Warfarin Dosage in a Group of Kuwaiti Individuals.
    Alrashid MH; Al-Serri A; Alshemmari SH; Koshi P; Al-Bustan SA
    Mol Diagn Ther; 2016 Apr; 20(2):183-90. PubMed ID: 26940072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
    Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Genetic and Non-Genetic Factors on Warfarin Dose Prediction in MENA Region: A Systematic Review.
    Bader LA; Elewa H
    PLoS One; 2016; 11(12):e0168732. PubMed ID: 27992547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between polymorphisms of VKORC1 and CYP2C9 genes with warfarin maintenance dose in a group of warfarin users in Birjand city, Iran.
    Fereidouni M; Moossavi M; Kazemi T; Nouranihassankiade S; Asghari A
    J Cell Biochem; 2019 Jun; 120(6):9588-9593. PubMed ID: 30525241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
    Ghozlan MF; Foad DA; Darwish YW; Saad AA
    Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
    Yamazaki H; Inoue K; Shimada T
    Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VKORC1 and CYP2C9 genotypes in Egyptian patients with warfarin resistance.
    Azzam H; Elwakeel H; Awad I; El-Farahaty R; El-Gilany AH; El-Sharawy S
    Blood Coagul Fibrinolysis; 2016 Mar; 27(2):121-6. PubMed ID: 24978953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Warfarin Metabolites in Patients Following Cardiac Valve Implantation: A Contribution of Clinical and Genetic Factors.
    Bryk A; Wypasek E; Awsiuk M; Maj D; Undas A
    Cardiovasc Drugs Ther; 2015 Jun; 29(3):257-64. PubMed ID: 25986145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and Enzymatic Activity Evaluation of a Novel
    Zhou XY; Lu XR; Li YH; Ma YQ; Zhao SW; Wang F; Xu RA; Hu GX; Cai JP
    Front Pharmacol; 2021; 12():619339. PubMed ID: 33643050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke.
    Supe S; Božina N; Matijević V; Bazina A; Mišmaš A; Ljevak J; Alvir D; Habek M; Poljaković Z
    J Neurol Sci; 2014 Aug; 343(1-2):30-5. PubMed ID: 24974237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.
    Tomek A; Maťoška V; Kolářová T; Neumann J; Srámek M; Sarbochová I; Táborský L; Bojar M; Goetz P; Serebruany VL
    Cardiology; 2013; 125(3):182-91. PubMed ID: 23774101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.